Shilpa Sharma1,2, Ronit Katz3, Alexander L Bullen4, Paulo H M Chaves5, Peter W de Leeuw6, Abraham A Kroon6, Alfons J H M Houben6, Michael G Shlipak7, Joachim H Ix4,8. 1. Division of Nephrology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California. 2. Nephrology Section, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, California. 3. University of Washington, Seattle, Washington. 4. Division of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, California. 5. Benjamin Leon Center for Geriatric Research and Education, Department of Translational Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida. 6. Department of Internal Medicine and CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, MD Maastricht, the Netherlands. 7. Department of Medicine, University of California San Francisco. 8. Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla, California.
Abstract
CONTEXT: Higher fibroblast growth factor-23 (FGF23) concentrations are associated with heart failure and mortality in diverse populations, but the strengths of associations differ markedly depending up on which assay is used. OBJECTIVE: We sought to evaluate whether iron deficiency, inflammation, or kidney function account for differences in the strengths of associations between these 2 FGF23 assays with clinical outcomes. DESIGN: Case cohort study from the Cardiovascular Health Study. SETTING: A total of 844 community-dwelling individuals aged 65 years or older with and without chronic kidney disease were followed for 10 years. OUTCOMES: Outcomes included death, incident heart failure (HF), and incident myocardial infarction (MI). Exposure was baseline intact and C-terminal FGF23. Using modified Cox models, adjusting sequentially we tested whether observed associations of each assay with outcomes were attenuated by iron status, inflammation, kidney function, or their combinations. RESULTS: FGF23 measured by either assay was associated with mortality in unadjusted analysis (intact FGF23 hazard ratio [HR] per 2-fold higher 1.45; 95% CI, 1.25-1.68; C-terminal FGF23 HR 1.38; 95% CI, 1.26-1.50). Adjustment for kidney function completely attenuated associations of intact FGF23 with mortality (HR 1.00; 95% CI, 0.85-1.17), but had much less influence on the association of C-terminal FGF23, for which results remained significant after adjustment (HR 1.15; 95% CI, 1.04-1.28). Attenuation was much less with adjustment for iron status or inflammation. Results were similar for the HF end point. Neither C-terminal or intact FGF23 was associated with MI risk. CONCLUSIONS: The relationship of FGF23 with clinical end points is markedly different depending on the type of FGF23 assay used. The associations of biologically active FGF23 with clinical end points may be confounded by kidney disease, and thus much weaker than previously thought. The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CONTEXT: Higher fibroblast growth factor-23 (FGF23) concentrations are associated with heart failure and mortality in diverse populations, but the strengths of associations differ markedly depending up on which assay is used. OBJECTIVE: We sought to evaluate whether iron deficiency, inflammation, or kidney function account for differences in the strengths of associations between these 2 FGF23 assays with clinical outcomes. DESIGN: Case cohort study from the Cardiovascular Health Study. SETTING: A total of 844 community-dwelling individuals aged 65 years or older with and without chronic kidney disease were followed for 10 years. OUTCOMES: Outcomes included death, incident heart failure (HF), and incident myocardial infarction (MI). Exposure was baseline intact and C-terminal FGF23. Using modified Cox models, adjusting sequentially we tested whether observed associations of each assay with outcomes were attenuated by iron status, inflammation, kidney function, or their combinations. RESULTS: FGF23 measured by either assay was associated with mortality in unadjusted analysis (intact FGF23 hazard ratio [HR] per 2-fold higher 1.45; 95% CI, 1.25-1.68; C-terminal FGF23 HR 1.38; 95% CI, 1.26-1.50). Adjustment for kidney function completely attenuated associations of intact FGF23 with mortality (HR 1.00; 95% CI, 0.85-1.17), but had much less influence on the association of C-terminal FGF23, for which results remained significant after adjustment (HR 1.15; 95% CI, 1.04-1.28). Attenuation was much less with adjustment for iron status or inflammation. Results were similar for the HF end point. Neither C-terminal or intact FGF23 was associated with MI risk. CONCLUSIONS: The relationship of FGF23 with clinical end points is markedly different depending on the type of FGF23 assay used. The associations of biologically active FGF23 with clinical end points may be confounded by kidney disease, and thus much weaker than previously thought. The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities:
Keywords:
FGF23; assays; inflammation; iron deficiency; kidney function; mortality
Authors: Charles Ginsberg; Timothy E Craven; Michel B Chonchol; Alfred K Cheung; Mark J Sarnak; Walter T Ambrosius; Anthony A Killeen; Kalani L Raphael; Udayan Y Bhatt; Jing Chen; Glenn M Chertow; Barry I Freedman; Suzanne Oparil; Vasilios Papademetriou; Barry M Wall; Clinton B Wright; Joachim H Ix; Michael G Shlipak Journal: Clin J Am Soc Nephrol Date: 2018-11-13 Impact factor: 8.237
Authors: Joachim H Ix; Ronit Katz; Bryan R Kestenbaum; Ian H de Boer; Michel Chonchol; Kenneth J Mukamal; Dena Rifkin; David S Siscovick; Mark J Sarnak; Michael G Shlipak Journal: J Am Coll Cardiol Date: 2012-06-13 Impact factor: 24.094
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Bryan Kestenbaum; Michael C Sachs; Andy N Hoofnagle; David S Siscovick; Joachim H Ix; Cassianne Robinson-Cohen; Joao A C Lima; Joseph F Polak; Marc Blondon; John Ruzinski; Denise Rock; Ian H de Boer Journal: Circ Heart Fail Date: 2014-03-25 Impact factor: 8.790
Authors: Erica L Clinkenbeard; Mark R Hanudel; Keith R Stayrook; Hitesh Nidumanda Appaiah; Emily G Farrow; Taryn A Cass; Lelia J Summers; Colin S Ip; Julia M Hum; Joseph C Thomas; Mircea Ivan; Briana M Richine; Rebecca J Chan; Thomas L Clemens; Ernestina Schipani; Yves Sabbagh; Linlin Xu; Edward F Srour; Marta B Alvarez; Melissa A Kacena; Isidro B Salusky; Tomas Ganz; Elizabeta Nemeth; Kenneth E White Journal: Haematologica Date: 2017-08-17 Impact factor: 11.047
Authors: Valentin David; Aline Martin; Tamara Isakova; Christina Spaulding; Lixin Qi; Veronica Ramirez; Kimberly B Zumbrennen-Bullough; Chia Chi Sun; Herbert Y Lin; Jodie L Babitt; Myles Wolf Journal: Kidney Int Date: 2016-01-04 Impact factor: 10.612
Authors: Shilpa Sharma; Ronit Katz; Charles Ginsberg; Alexander Bullen; Volker Vallon; Scott Thomson; Orson W Moe; Andrew N Hoofnagle; Peter W de Leeuw; Abraham A Kroon; Alfons J H M Houben; Joachim H Ix Journal: J Bone Miner Res Date: 2022-04-25 Impact factor: 6.390
Authors: Matthias B Moor; Nasser A Dhayat; Simeon Schietzel; Michael Grössl; Bruno Vogt; Daniel G Fuster Journal: Urolithiasis Date: 2022-02-24 Impact factor: 2.861